Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cimex, a business unit of Schweizerhall Holding, has received the first approval from the Federal Institute for Drugs and Medical Devices, Germany for the antiplatelet agent clopidogrel.
Subscribe to our email newsletter
Two marketing partners are expected to launch clopidogrel (original product: Plavix/Iscover by Bristol-Myers Squibb/Sanofi-Aventis) in Germany. Applications for approval in additional European countries are in preparation.
Luzi von Bidder, chairman of the board of Schweizerhall Holding, said: “The approval of clopidogrel in Germany represents a milestone for the Schweizerhall Group. Clopidogrel, developed by Cimex, will be the first more cost-effective alternative of this drug in the German market.”